ClinicalTrials.gg
RecruitingNCT04375800Updated Oct 27, 2026

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

A Phase 2 interventional study of Doravirine and 2 NRTIs in Human Immunodeficiency Virus (HIV) Infection, sponsored by Merck Sharp & Dohme LLC. Recruiting at 26 sites in 8 countries. Open to participants aged 4 Weeks to 11 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.
Updated Oct 27, 2026First sites in Dominican Republic and Guatemala2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
4 Weeks to 11 Years
Sex
All
01

Study summary

This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to \<12 years and weighing \<45 kg, who are treatment-naive (TN) or have been virologically suppressed (VS) on stable combination antiretroviral therapy (cART) for ≥3 months with no history of treatment failure. The primary objectives are:

  • To evaluate the steady state pharmacokinetics (PK) of doravirine (DOR) [MK-1439] when given in combination with 2 nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs) or as part of the fixed-dose combination (FDC) of DOR/lamivudine (3TC)/tenofovir disproxil fumarate (TDF) in participants ≥6 to \<12 years and weighing ≥14 to \<45 kg.
  • To evaluate the safety and tolerability of DOR when given with 2 NRTIs or as part of the FDC of DOR/3TC/TDF, in participants ≥6 to 12 years and weighing ≥14 to \<45 kg, through Week 24.
Read the detailed description

Participants who complete the Week 96 visit will be eligible to enroll in an Extension Study and receive DOR until it is commercially available, or for up to an additional 224 weeks (whichever comes first).

02

Conditions studied

  • Human Immunodeficiency Virus (HIV) Infection

Browse trials for

03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.

This study's planned enrollment of 84 is below the median of 96 across 2,252 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
4 Weeks to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has type 1 (HIV-1) infection confirmed at screening
  • Has appropriate treatment history defined as treatment-naïve (TN) or with documented virologic suppression (HIV-1 ribonucleic acid [RNA] \<50 copies/mL) on stable combination antiretroviral therapy (cART) for ≥3 months
  • Body weight is >3 kg to \<45 kg
  • If female, is not pregnant or breastfeeding, and one of the following applies:
  • Is not a woman of (WOCBP)
  • Is a WOCBP using an acceptable form of , or is abstinent
  • If a WOCBP must have a negative pregnancy test (urine or serum) within 24 hours of the first dose of study intervention

Study Extension Inclusion Criteria:

  • Has completed the Week 96 visit
  • Is considered, in the opinion of the investigator, to have derived benefit from treatment with doravirine (DOR) plus the 2 nucleoside/nucleotide analog reverse transcriptase inhibitor (NRTIs) selected by the investigator, or doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF), by Week 96 of the study
  • Is considered, in the opinion of the investigator, to be a clinically appropriate candidate for additional treatment with DOR regimens (DOR plus 2 NRTIs selected by the investigator or DOR/3TC/TDF)
  • Understands the procedures in the study extension and has provided (or have the participant's legally acceptable representative, if applicable, provide) documented /assent to enter the study extension and continue treatment with DOR regimens (DOR plus 2 NRTIs selected by the investigator or DOR/3TC/TDF) until it is available locally in countries participating in the study or for up to an additional 224 weeks (whichever comes first)

Exclusion criteria

Exclusion Criteria:

  • Has evidence of renal disease
  • Demonstrates evidence of liver disease
  • Has clinical or laboratory evidence of pancreatitis
  • Has any history of
  • Has presence of any active acquired immunodeficiency syndrome (AIDS)-defining opportunistic Infection
  • Has an active diagnosis of hepatitis, including co-infection
  • Has current active tuberculosis and/or is being treated with a rifampicin-containing regimen
  • Has a medical condition that precludes absorption or intake of oral pellets/granules
  • Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound results of the study or interfere with participating for the entire duration of the study
  • Is taking or is anticipated to require systemic therapy, immune modulators, or other prohibited therapy
  • Is currently participating in or has participated in an interventional clinical study with an compound or device from 45 days prior to Day 1 through the treatment period
  • Has a documented or known virologic resistance to DOR
  • Has any history of viremia ( RNA >1000 copies/mL) after at least 3 months on a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Doravirine as a single entity plus 2 NRTIs or Doravirine as a FDC with 3TC and TDF

    Participants receive doravirine (DOR) at 7.2 mg to 100 mg, based on weight, PLUS 2 nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs), based on local label, for 96 weeks, OR a fixed-dose combination (FDC) of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF), based on weight, for 96 weeks.

    Drug: Doravirine · Drug: 2 NRTIs · Drug: DOR/3TC/TDF

Interventions

  • Administered orally

    Also known as: MK-1439

  • Drug2 NRTIs

    Administered orally

  • DrugDOR/3TC/TDF

    Drug pages: Lamivudine · Tenofovir

    Administered orally

    Also known as: MK-1439A

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve (AUC) From 0 to 24 Hours Postdose (AUC0-24hr) of Doravirine (DOR) Following Once-Daily Dosing in Plasma at Steady-State

    Per protocol, intensive pharmacokinetic (PK) sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine AUC0-24hr.

    Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose

  2. Maximum Concentration (Cmax) of DOR Following Once-Daily Dosing in Plasma at Steady-State

    Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine Cmax.

    Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose

  3. Concentration at 24 Hours (C24) of DOR Following Once-Daily Dosing in Plasma at Steady-State

    Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine C24.

    Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose

  4. Time to Maximum Concentration (Tmax) of DOR Following Once-Daily Dosing in Plasma at Steady-State

    Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine Tmax.

    Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose

  5. AUC From 0 to 12 Hours Postdose (AUC0-12hr) of DOR Following Twice-Daily Dosing in Plasma at Steady-State

    Per protocol, intensive PK sampling includes multiple blood samples collected up to 12 hours postdose at a single visit to determine AUC0-12hr.

    Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose

  6. Cmax of DOR Following Twice-Daily Dosing in Plasma at Steady-State

    Per protocol, intensive PK sampling includes multiple blood samples collected up to 12 hours postdose at a single visit to determine Cmax.

    Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose

  7. Concentration at 12 Hours (C12) of DOR Following Twice-Daily Dosing in Plasma at Steady-State

    Per protocol, intensive PK sampling includes multiple blood samples collected up to 12 hours postdose at a single visit to determine C12.

    Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose

  8. Tmax of DOR Following Twice-Daily Dosing in Plasma at Steady-State

    Per protocol, intensive PK sampling includes multiple blood samples collected up to 12 hours postdose at a single visit to determine Tmax.

    Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose

  9. Percentage of Participants With ≥1 Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.

    Time frame: Up to 24 weeks

  10. Percentage of Participants With a Grade 3 or 4 AE

    Grade 3 or 4 AEs are "severe symptoms that cause inability to perform usual social and functional activities with intervention or hospitalization indicated" (Grade 3), or "potentially life-threatening events" (Grade 4).

    Time frame: Up to 24 weeks

  11. Percentage of Participants With Events of Death

    The percentage of participants with events of death at Week 24 will be reported.

    Time frame: Up to 24 weeks

  12. Percentage of Participants Discontinuing From Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.

    Time frame: Up to 24 weeks

  13. Percentage of Participants Discontinuing From Study Intervention Due to a Drug-Related AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered to be related to the study interventions.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Plasma Concentration of DOR

    Per protocol, sparse PK sampling includes up to 2 blood samples collected at multiple visits up to 24 weeks.

    Time frame: Sparse pharmacokinetic sampling: at designated timepoints up to 24 weeks

  2. Plasma Concentration of Lamivudine (3TC) Following Once-Daily Dosing of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) as an Age-Appropriate Fixed-Dose Combination (FDC)

    Per protocol, sparse PK sampling includes up to 2 blood samples collected at multiple visits up to 24 weeks.

    Time frame: Sparse pharmacokinetic sampling: at designated timepoints up to 24 weeks

  3. Plasma Concentration of Tenofovir (TFV) Following Once-Daily Dosing of DOR/3TC/TDF as an Age-Appropriate FDC

    Per protocol, sparse PK sampling includes up to 2 blood samples collected at multiple visits up to 24 weeks.

    Time frame: Sparse pharmacokinetic sampling: at designated timepoints up to 24 weeks

  4. AUC0-24hr of 3TC Following Once-Daily Dosing of DOR/3TC/TDF as an Age-Appropriate FDC

    Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine AUC0-24hr of 3TC.

    Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose

  5. AUC0-24hr of TFV Following Once-Daily Dosing of DOR/3TC/TDF as an Age-Appropriate FDC

    Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine AUC0-24hr of TFV.

    Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose

  6. Cmax of 3TC Following Once-Daily Dosing of DOR/3TC/TDF as an Age-Appropriate FDC

    Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine Cmax of 3TC.

    Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose

  7. Cmax of TFV Following Once-Daily Dosing of DOR/3TC/TDF as an Age-Appropriate FDC

    Per protocol, intensive PK sampling includes multiple blood samples collected up to 24 hours postdose at a single visit to determine Cmax of TFV.

    Time frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose

  8. Percentage of Participants With ≥1 AE at Week 48

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.

    Time frame: Up to 48 weeks

  9. Percentage of Participants With ≥1 AE at Week 96

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.

    Time frame: Up to 96 weeks

  10. Percentage of Participants With Grade 3 or 4 AE at Week 48

    Grade 3 or 4 AEs are "severe symptoms that cause inability to perform usual social and functional activities with intervention or hospitalization indicated" (Grade 3), or "potentially life-threatening events" (Grade 4).

    Time frame: Up to 48 weeks

  11. Percentage of Participants With Grade 3 or 4 AE at Week 96

    Grade 3 or 4 AEs are "severe symptoms that cause inability to perform usual social and functional activities with intervention or hospitalization indicated" (Grade 3), or "potentially life-threatening events" (Grade 4).

    Time frame: Up to 96 weeks

  12. Percentage of Participants With Events of Death at Week 48

    The percentage of participants with events of death at Week 48 will be reported.

    Time frame: Up to 48 weeks

  13. Percentage of Participants With Events of Death at Week 96

    The percentage of participants with events of death at Week 96 will be reported.

    Time frame: Up to 96 weeks

  14. Percentage of Participants Discontinuing From Study Intervention Due to AE at Week 48

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.

    Time frame: Up to 48 weeks

  15. Percentage of Participants Discontinuing from Study Intervention Due to AE at Week 96

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study interventions.

    Time frame: Up to 96 weeks

  16. Percentage of Participants Discontinuing From Study Intervention Due to Drug-Related AE at Week 48

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered to be related to the study interventions.

    Time frame: Up to 48 weeks

  17. Percentage of Participants Discontinuing From Study Intervention Due to Drug-Related AE at Week 96

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, that is considered to be related to the study interventions.

    Time frame: Up to 96 weeks

  18. Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL at Week 24

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time polymerase chain reaction (PCR) assay with a lower limit of detection of 40 copies/mL.

    Time frame: Up to 24 weeks

  19. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.

    Time frame: Up to 48 weeks

  20. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.

    Time frame: Up to 96 weeks

  21. Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 24

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.

    Time frame: Up to 24 weeks

  22. Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.

    Time frame: Up to 48 weeks

  23. Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.

    Time frame: Up to 96 weeks

  24. Percentage of Participants With HIV-1 RNA ≥50 copies/mL at Week 24

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.

    Time frame: Up to 24 weeks

  25. Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 48

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.

    Time frame: Up to 48 weeks

  26. Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 96

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.

    Time frame: Up to 96 weeks

  27. Percentage of Participants With Log10 Drop in Plasma HIV-1 RNA From Baseline at Week 24

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.

    Time frame: Baseline (Day 1) and Week 24

  28. Percentage of Participants With Log10 Drop in Plasma HIV-1 RNA From Baseline at Week 48

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.

    Time frame: Baseline (Day 1) and Week 48

  29. Percentage of Participants With Log10 Drop in Plasma HIV-1 RNA From Baseline at Week 96

    Plasma HIV-1 RNA quantification will be performed at the central laboratory using a real-time PCR assay with a lower limit of detection of 40 copies/mL.

    Time frame: Baseline (Day 1) and Week 96

  30. Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 24

    CD4+ T-cell counts will be performed at the central laboratory.

    Time frame: Baseline (Day 1) and Week 24

  31. Change From Baseline in CD4+ T-Cell Counts at Week 48

    CD4+ T-cell counts will be performed at the central laboratory.

    Time frame: Baseline (Day 1) and Week 48

  32. Change From Baseline in CD4+ T-Cell Counts at Week 96

    CD4+ T-cell counts will be performed at the central laboratory.

    Time frame: Baseline (Day 1) and Week 96

  33. Viral Resistance-Associated Substitutions (RASs) to DOR or Other Treatment Components

    The presence of viral RASs to DOR or other treatment components will be monitored for up to 96 weeks.

    Time frame: Up to 96 weeks

  34. Percentage of Participants Adhering to DOR or to the FDC of DOR/3TC/TDF

    Adherence to DOR or to the FDC of DOR/3TC/TDF will be monitored for up to 96 weeks.

    Time frame: Up to 96 weeks

  35. Assessment of Palatability/Acceptability of Oral Pellets/Granules of DOR or the FDC of DOR/3TC/TDF

    Palatability/acceptability will be based on scores on the 5-point facial hedonic scale (FHS). FHS scores will be tabulated and summarized by mean and standard deviation (SD), on Day 28. The highest possible FHS score is 5, with higher scores indicative of greater palatability.

    Time frame: Day 28

07

Study locations

13 of 26 sites recruiting
  • University of Colorado at Denver ( Site 0108)
    Aurora, Colorado 80045, United States
    Completed

    Not enrolling at this site — choose another above.

  • Emory Children's Center ( Site 0103)
    Atlanta, Georgia 30322, United States
    Recruiting
    • Study Coordinator · Contact404-727-5642
  • Clinica Somer ( Site 1003)
    Rionegro, Antioquia 054040, Colombia
    Recruiting
    • Study Coordinator · Contact+573235903405
  • Ciensalud Ips S A S ( Site 1001)
    Barranquilla, Atlántico 080020, Colombia
    Recruiting
    • Study Coordinator · Contact573183894721
  • CEIP - Centro de Estudios en Infectología Pediátrica ( Site 1002)
    Cali, Valle del Cauca Department 760042, Colombia
    Completed

    Not enrolling at this site — choose another above.

  • Instituto Dermatológico y Cirugía de Piel "Dr. Huberto Bogaert Díaz" ( Site 1100)
    Santo Domingo, 10306, Dominican Republic
    Recruiting
    • Study Coordinator · Contact+18095703439
  • Clínica Médica Especializada en Pediatría e Infectología Pediátrica - Dr. Mario Melgar ( Site 1201)
    Guatemala City, 01009, Guatemala
    Recruiting
    • Study Coordinator · Contact+50223196600
  • Instituto Nacional de Pediatria ( Site 0701)
    Coyoacán, Mexico City 04530, Mexico
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Infantil de Mexico Federico Gomez ( Site 0702)
    Mexico City, Mexico City 06720, Mexico
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Unidad de Atencion Medica e Investigacion en Salud S.C. ( Site 0700)
    Mérida, Yucatán 97000, Mexico
    Completed

    Not enrolling at this site — choose another above.

  • Kuzbasskiy Center for the Prevention and Control of AIDS ( Site 0506)
    Kemerovo, Kemerovo Oblast 650056, Russia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clinical Centre for Prevention and Control of AIDS ( Site 0504)
    Krasnodar, Krasnodarskiy Kray 350015, Russia
    Completed

    Not enrolling at this site — choose another above.

  • Krasnoyarsk Regional Center for Prevention and Control of AIDS ( Site 0507)
    Krasnoyarsk, Krasnoyarsk Krai 660049, Russia
    Completed

    Not enrolling at this site — choose another above.

  • Infectious Clinical Hospital #2 ( Site 0501)
    Moscow, Moscow 105275, Russia
    Completed

    Not enrolling at this site — choose another above.

  • FGU Republican Clinical Infectious Hospital of Roszdrav ( Site 0500)
    Saint Petersburg, Sankt-Peterburg 196645, Russia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • FARMOVS PTY LTD ( Site 0601)
    Bloemfontein, Free State 9301, South Africa
    Completed

    Not enrolling at this site — choose another above.

  • Perinatal HIV Research Unit ( Site 0602)
    Johannesburg, Gauteng 1864, South Africa
    Recruiting
    • Study Coordinator · Contact+2711 989 9700
  • Wits Reproductive Health and HIV Institute (WRHI) ( Site 0603)
    Johannesburg, Gauteng 2001, South Africa
    Recruiting
    • Study Coordinator · Contact+27 11 358 5300
  • Empilweni Services and Research Unit ( Site 0604)
    Johannesburg, Gauteng 2093, South Africa
    Completed

    Not enrolling at this site — choose another above.

  • King Edward Hospital ( Site 0600)
    Durban, KwaZulu-Natal 4001, South Africa
    Recruiting
    • Study Coordinator · Contact+27312611093
  • Family Clinic Research With UBUNTU ( Site 0605)
    Cape Town, Western Cape 7505, South Africa
    Recruiting
    • Study Coordinator · Contact+27219384153
  • Be Part Yoluntu Centre ( Site 0606)
    Paarl, Western Cape 7626, South Africa
    Recruiting
    • Study Coordinator · Contact+2782 660 5795
  • Tsitsikamma Clinical Research Initiative (TCRI) ( Site 0607)
    Plettenberg Bay, Western Cape 6600, South Africa
    Completed

    Not enrolling at this site — choose another above.

  • Siriraj Hospital ( Site 0901)
    Bangkok, Bangkok 10700, Thailand
    Recruiting
    • Study Coordinator · Contact+6624180545
  • Research Institute for Health Sciences ( Site 0902)
    Chiang Mai, 50200, Thailand
    Recruiting
    • Study Coordinator · Contact+6653936148
  • Faculty of Medicine - Khon Kaen University ( Site 0903)
    Khon Kaen, 40002, Thailand
    Recruiting
    • Study Coordinator · Contact+66897112236
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Nov 2028, 93 months after the start.

Of 29 industry-sponsored phase 2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 93 months is above that.

Counting every sponsor, half of 86 studies reached it within 36 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2020
First posted
May 5, 2020
StartActual
Feb 3, 2021
Primary completionEst.
Nov 12, 2028
CompletionEst.
Apr 11, 2034
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added — first sites in Dominican Republic and Guatemala
Show 2 added (1 Dominican Republic, 1 Guatemala)
  • Instituto Dermatológico y Cirugía de Piel "Dr. Huberto Bogaert Díaz" ( Site 1100) · Santo Domingo, Dominican Republic
  • Clínica Médica Especializada en Pediatría e Infectología Pediátrica - Dr. Mario Melgar ( Site 1201) · Guatemala City, Guatemala
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    2 sites added — first sites in Dominican Republic and Guatemala
    Show 2 added (1 Dominican Republic, 1 Guatemala)
    • Instituto Dermatológico y Cirugía de Piel "Dr. Huberto Bogaert Díaz" ( Site 1100) · Santo Domingo, Dominican Republic
    • Clínica Médica Especializada en Pediatría e Infectología Pediátrica - Dr. Mario Melgar ( Site 1201) · Guatemala City, Guatemala
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04375800
Responsible party
Sponsor
First posted
May 5, 2020
Start date
Feb 3, 2021
Primary completion
Nov 12, 2028 (estimated)
Completion
Apr 11, 2034 (estimated)
Last update
Oct 27, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doravirine · Lamivudine · Tenofovir

Start the discussion